Will be interesting to see how MESO goes on the US markets.
I would also like to see larger testing, instead of 12 patients, how about 1,200 patients. Then we can see an aggregated result to be expected across the board.
Great announcement not just for holders, but also those on ventilators.
I would like to see how affordable / how easily this can be commercialised globally as well. While a number of advanced economies are starting to flatten the curve, what about those countries who are just beginning to enter the curve, or whether there is another spike...
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-50
-
- There are more pages in this discussion • 798 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.307B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $1.921M | 1.665M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29121 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 12839 | 14 |
View Market Depth
| Last trade - 11.41am 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |